AABB

Behind every AABB publication is a group of people doing the unglamorous work of getting it right. This summer, before the new AABB Biotherapies Manual went to press, editors David McKenna Jr, MD, CABP(H), and David Stroncek, MD, joined colleagues from AABB’s biotherapies, regulatory affairs, standards and publications teams for a final review. Over several days, the team reviewed the science, checked pagination, caught symbols that can get lost in layout, and made sure each chapter reflected the latest regulatory and medical updates. It’s meticulous work, but it matters. The result is a first-of-its-kind reference for developing and producing cellular and biotherapy products, bringing current science, standards and regulatory considerations together in one resource. After months of development and this final review, the AABB Biotherapies Manual is now ready to support professionals across the biotherapies field. Order your copy in the AABB Store: https://bit.ly/4xG2M0h #Biotherapies #CellTherapy

Biotherapies are increasingly targeting the biology underneath disease rather than its downstream effects, drawing cellular therapy, immunology and transfusion medicine closer together. What does that mean for the professionals working across these fields? In this sponsored edition of CellSource, Christina Celluzzi, PhD, MS, CABP(H), and Leona Ling, PhD, explore FcRn-blocker therapies and what this evolving class may mean for the transfusion medicine community. Also inside: three open-mic conversations coming to the Biotherapies Pavilion at #AABB2026, the first Transfusion supplement devoted entirely to biotherapies and the new AABB Biotherapies Manual. #CellTherapy #Biotherapies #Immunology

Cell therapy programs are becoming more complex, with more therapies, more data and more handoffs. What does that mean for the systems and workflows needed to support them? In this edition of CellSource, Christina Celluzzi, PhD, MS, CABP(H), speaks with Bruno Rousselin, CEO of Gpi USA, about the day-to-day realities facing cell therapy programs and what teams may get wrong when they move to paperless. Also inside: five questions shaping biotherapies ahead of #AABB2026, how a new partnership aims to bring cell therapy collections closer to patients, and the access, infrastructure and workforce challenges that will shape what comes next for advanced therapies. #CellSource #CellTherapy #Biotherapies

What if the biggest change in cell therapy isn’t where it’s being used, but what it’s being designed to do? In the latest CellSource, Christina Celluzzi, PhD, MS, CABP(H), introduces the “Four Rs” of cell therapy, a framework for thinking about the next chapter of living medicines as they evolve beyond oncology. Also inside: a preview of Fred Appelbaum's Annual Meeting keynote on how bone marrow transplantation shaped modern biotherapies, the latest FDA and global regulatory news, recognition for AABB's CABP program and a new edition of the Technical Manual. #AABBCellSource #Biotherapies #CellTherapy

What should we be talking about next? In this month's CellSource, Christina Celluzzi, PhD, MS, CABP(H) reflects on a challenge facing the biotherapies field: not a shortage of important topics, but an abundance of them. This issue also includes updates on #AABB2026, Cord Blood Awareness Month resources, quality systems discussions at the upcoming CGT Summit and more. What topics would you like to see explored in future editions of CellSource? Read the latest issue and join the conversation. #Biotherapies #CellTherapy

AABB is pleased to share a limited-time offer for biotherapies professionals considering AABB’s Certified Advanced Biotherapies Professional (CABP) Credentialing Program. Approved applicants who submit a CABP application by June 30 will receive a free exam retake voucher. AABB’s CABP is the first and only credential for biotherapies professionals, designed to validate expertise and support career growth in this rapidly evolving field. Start your CABP journey: https://bit.ly/4g1cNjk #AABBcabp #Biotherapies #CellTherapy